The incremental clinical advantage from CAPTAIN (penile length preservation, plus prior erectile/continence results) supports broader TULSA adoption and may drive procedure volume growth. The stock could trade up near-term as analysts update models. Key catalyst to watch: 1-year primary safety endpoint and 3-year primary efficacy endpoint of CAPTAIN.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 24 $7.26entry
- T+1 · 4mo ago +0.96%α +0.94% · $7.33
- T+5 · 4mo ago −0.14%α −0.51% · $7.25
- T+20 · 3mo ago −6.47%α −10.10% · $6.79
- T+60 · 29d ago −19.28%α −22.57% · $5.86
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Profound Medical announced new CAPTAIN trial data showing statistically significant superior penile length preservation with the TULSA Procedure vs robotic radical prostatectomy (no median change vs 0.65 cm reduction at 1 month, p<0.001). This adds to previously reported safety endpoint advantages in erectile function and urinary continence, strengthening the clinical value proposition for TULSA.
Key Facts
- CAPTAIN trial: no median change in penile length at 1 month after whole-gland TULSA vs 0.65 cm median reduction after robotic RP
- Between-arm difference statistically significant (0.42 cm, p<0.001)
- Data presented at Society of Robotic Surgery Annual Meeting, July 24, 2026
- Previously announced CAPTAIN primary safety endpoint showed TULSA superiority in preserving erectile function and urinary continence at 6 months
Financial Impact
Positive clinical data strengthens TULSA's competitive position vs robotic prostatectomy but no financial figures disclosed in this filing
Risk Factors
- CAPTAIN primary efficacy endpoint (3-year treatment-free survival) remains unread
- Market adoption and reimbursement decisions may lag clinical data
- Competitive response from robotic surgery platforms
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (PROF), Batch item 1 | 0001171843-26-004863 |
| Exhibit: exh_991.htm | 0001171843-26-004863 |
| Document: 0001171843-26-004863-index-headers.html | 0001171843-26-004863 |
| Document: 0001171843-26-004863-index.html | 0001171843-26-004863 |
| Document: 0001171843-26-004863.txt | 0001171843-26-004863 |
| 8-K Filing (PROF), Batch item 6 | 0001171843-26-004863 |
| Exhibit: exh_991.htm | 0001171843-26-004863 |
| Document: 0001171843-26-004863-index-headers.html | 0001171843-26-004863 |
| Document: 0001171843-26-004863-index.html | 0001171843-26-004863 |
| Document: 0001171843-26-004863.txt | 0001171843-26-004863 |
Track record
22 reports on PROF
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $7.44 Now $7.34 −1.34% settles Dec 11
- Nov 9, 20267d ago 8-K Neutral 2/10 Entry $7.34 Now $7.34 +0.00% settles Dec 8
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $7.21 Now $7.34 −1.80% settles Dec 7
- Nov 3, 202613d ago 8-K Neutral 4/10 Entry $7.16 Now $7.34 +2.51% settles Dec 3
- Oct 30, 202617d ago Press Release Neutral 4/10 Entry $6.57 Now $7.34 +11.72% settles Nov 30
- Oct 22, 202625d ago 8-K Neutral 2/10 Entry $5.56 Now $7.34 +32.01% settles Nov 20
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $6.62 to $7.68 Now $7.34 +10.88% ▲ +16.01% +18.57% vs SPY
- Oct 9, 20265w ago 8-K Neutral 3/10 Entry $6.90 to $7.01 Now $7.34 +6.38% ▲ +1.59% +7.15% vs SPY
- Oct 7, 20265w ago 8-K Bullish 7/10 Entry $6.91 to $7.16 Now $7.34 +6.22% ▲ +3.62% +8.91% vs SPY
- Sep 3, 202610w ago 8-K Neutral 2/10 Entry $6.89 to $6.03 Now $7.34 +6.53% ▼ −12.48% −13.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers